| NUM |
TITLE |
DATE |
VIEW |
| 24 |
Celltrion–MustBio Collaborate on PD-1×VEGF×IL-2v Cancer Therapy
|
2025-11-20 |
12 |
| 23 |
MB7 Project Selected for the 2025 Cancer Efficacy Evaluation/Consulting Service Program
|
2025-06-19 |
275 |
| 22 |
Mustbio Presents Promising Preclinical Results of Its Novel αPD-1/αVEGF/IL-2v Tri-Specific Fusion Protein at AACR 2025
|
2025-05-22 |
498 |
| 21 |
Mustbio to Present Preclinical Data on ‘PD-1/VEGF/IL-2v’ Tri-Specific Fusion Protein at AACR (Biospectator 2025.04.21)
|
2025-04-22 |
390 |
| 20 |
MustBio Selected for J&J JLABS Korea Program
|
2025-01-10 |
395 |
| 19 |
Project MB5029 selected as National New Drug Development Project
|
2024-11-25 |
430 |
| 18 |
MUSTBIO Presents Promising Preclinical Data on its αPD-1/IL-2v at SITC 2024 (Biospectator, 2024.11.14)
|
2024-11-15 |
1284 |
| 17 |
Publication of pre-clinical study results of a novel anti-PD-L1 x IL-2v bispecific fusion protein
|
2024-06-05 |
2416 |
| 16 |
MustBio introduced a novel aPD-1 x IL-2v at the American Association for Cancer Research (AACR) Annual Meeting 2024. (Biospectator, 2024.04.23)
|
2024-04-23 |
1472 |
| 15 |
Patent registered at Korea Intellectual Property Office regarding IL-2v based multi-specific fusion protein
|
2024-04-16 |
1525 |
| 14 |
Mustbio presents aPD-1 x IL-2v study results at 2024 AACR Annual Meeting
|
2024-04-15 |
1804 |
| 13 |
MustBio introduced a novel aPD-L1 x CD3 at the American Association for Cancer Research (AACR) Annual Meeting 2023. (Biospectator, 2023.05.12)
|
2023-05-12 |
1738 |
| 12 |
[Notice] Announcement of convocation of annual general meeting of shareholders (2023.03.07)
|
2024-03-07 |
1043 |
| 11 |
[Notice] New stock issuance (2023.03.07)
|
2023-03-07 |
909 |
| 10 |
[Notice] New stock issuance (2023.02.27)
|
2023-02-27 |
930 |
| 9 |
Mustbio signs a CDO contract with Protium to develop new bispecific antibody (Biospectator, 2023.01.05)
|
2023-01-09 |
736 |
| 8 |
Solid PoC data required to attract biotech investment (Hitnews, 2023.01.02)
|
2023-01-09 |
4286 |
| 7 |
Mustbio raises KRW 16.5 billion in Series B to develop multispecific antibodies (Biospectator, 2022.12.08)
|
2022-12-30 |
615 |
| 6 |
[Notice] New stock issuance (2022.11.15)
|
2022-11-15 |
462 |
| 5 |
IR presentation at Korea Bio Investment Conference (2022.07.11)
|
2022-07-22 |
690 |
